Rosenthal, A
Luthi, J
Belohlavek, M
Kortüm, K M
Mookadam, F
Mayo, A
Fonseca, R
Bergsagel, P L
Reeder, C B
Mikhael, J R
Stewart, A K
Article History
Received: 13 October 2015
Revised: 30 November 2015
Accepted: 4 December 2015
First Online: 15 January 2016
Competing interests
: KAS is a consultant for Celgene, Novartis, BMS and AMGEN. LB is a consultant for Onyx. RF is a consultant for Medtronic, Otsuka, Celgene, Genzyme, BMS, Lilly, Onyx, Binding Site, Millenium and AMGEN, and has received research funding from Cylene and Onyx. JM has received research funding from Celgene, Abbvie, Onyx, and Sanofi. The remaining authors declare no conflict of interest.